"Apolipoprotein E4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A major and the second most common isoform of apolipoprotein E. In humans, Apo E4 differs from APOLIPOPROTEIN E3 at only one residue 112 (cysteine is replaced by arginine), and exhibits a lower resistance to denaturation and greater propensity to form folded intermediates. Apo E4 is a risk factor for ALZHEIMER DISEASE and CARDIOVASCULAR DISEASES.
| Descriptor ID |
D053327
|
| MeSH Number(s) |
D10.532.091.500.750 D12.776.070.400.500.750 D12.776.521.120.500.750
|
| Concept/Terms |
Apolipoprotein E4- Apolipoprotein E4
- Apolipoprotein E-4
- Apolipoprotein E 4
- Apo E4
- ApoE4
- Apo E epsilon 4
- Apo E-4
- Apo E 4
|
Below are MeSH descriptors whose meaning is more general than "Apolipoprotein E4".
Below are MeSH descriptors whose meaning is more specific than "Apolipoprotein E4".
This graph shows the total number of publications written about "Apolipoprotein E4" by people in this website by year, and whether "Apolipoprotein E4" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 2 | 1 | 3 |
| 2017 | 1 | 1 | 2 |
| 2019 | 2 | 0 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 4 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Apolipoprotein E4" by people in Profiles.
-
Association of APOE e4 Status With Long-term Declines in Odor Sensitivity, Odor Identification, and Cognition in Older US Adults. Neurology. 2023 09 26; 101(13):e1341-e1350.
-
Sex and APOE e4 carrier effects on atrophy, amyloid PET, and tau PET burden in early-onset Alzheimer's disease. Alzheimers Dement. 2023 11; 19 Suppl 9:S49-S63.
-
Profiling baseline performance on the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection. Alzheimers Dement. 2023 11; 19 Suppl 9:S8-S18.
-
Interaction analysis of ancestry-enriched variants with APOE-?4 on MCI in the Study of Latinos-Investigation of Neurocognitive Aging. Sci Rep. 2023 03 29; 13(1):5114.
-
Refining Risk for Alzheimer's Disease Among Heterozygous APOE?4 Carriers. J Alzheimers Dis. 2023; 94(2):483-489.
-
Rapid olfactory decline during aging predicts dementia and GMV loss in AD brain regions. Alzheimers Dement. 2023 04; 19(4):1479-1490.
-
Memory Resilience in Alzheimer Disease With Primary Progressive Aphasia. Neurology. 2021 02 09; 96(6):e916-e925.
-
Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis. Curr Atheroscler Rep. 2020 07 25; 22(9):48.
-
APOE is a correlate of phenotypic heterogeneity in Alzheimer disease in a national cohort. Neurology. 2020 02 11; 94(6):e607-e612.
-
APOE e4-specific associations of VEGF gene family expression with cognitive aging and Alzheimer's disease. Neurobiol Aging. 2020 03; 87:18-25.